Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 63% bullish and 36%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $90,860, and 10, calls, for a total amount of $455,657.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $175.0 for AbbVie over the last 3 months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $175.0 in the last 30 days.
AbbVie Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
ABBV | PUT | SWEEP | BEARISH | 11/15/24 | $7.7 | $7.65 | $7.7 | $160.00 | $90.8K | 271 | 0 |
ABBV | CALL | SWEEP | BEARISH | 01/16/26 | $22.95 | $22.2 | $22.2 | $155.00 | $82.1K | 137 | 37 |
ABBV | CALL | TRADE | BULLISH | 08/16/24 | $1.39 | $1.25 | $1.39 | $175.00 | $59.4K | 4.1K | 438 |
ABBV | CALL | TRADE | BULLISH | 07/19/24 | $5.15 | $4.95 | $5.1 | $160.00 | $56.1K | 285 | 135 |
ABBV | CALL | SWEEP | BULLISH | 06/21/24 | $0.63 | $0.58 | $0.63 | $170.00 | $47.2K | 5.2K | 1.0K |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Where Is AbbVie Standing Right Now?
With a trading volume of 2,513,831, the price of ABBV is down by -0.88%, reaching $161.5.
Current RSI values indicate that the stock is may be approaching oversold.
Next earnings report is scheduled for 64 days from now.
What Analysts Are Saying About AbbVie
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $189.0.
Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $200.
Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on AbbVie with a target price of $187.
An analyst from BMO Capital persists with their Outperform rating on AbbVie, maintaining a target price of $180.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.
有大量資金可以花的投資者對艾伯維（紐約證券交易所代碼：ABBV）採取了看漲立場。
零售交易者應該知道。
今天，當我們在本辛加追蹤的公開期權歷史記錄中出現頭寸時，我們注意到了這一點。
無論這些是機構還是僅僅是富人，我們都不知道。但是，當ABBV發生這麼大的事情時，通常意味着有人知道某件事即將發生。
今天，本辛加的期權掃描儀發現了艾伯維的11筆期權交易。
這不正常。
這些大手交易者的整體情緒分爲63％看漲和36％（看跌）。
在我們發現的所有期權中，有1個看跌期權，總額爲90,860美元，還有10個看漲期權，總額爲455,657美元。
預測的價格區間
考慮到這些合約的交易量和未平倉合約，在過去的3個月中，鯨魚似乎一直將AbbVie的價格定在150.0美元至175.0美元之間。
對交易量和未平倉合約的見解
在交易期權時，查看交易量和未平倉合約是一個強有力的舉動。這些數據可以幫助您跟蹤給定行使價下艾伯維期權的流動性和利息。下面，我們可以觀察過去30天內，艾伯維所有鯨魚交易的看漲期權和看跌期權交易量和未平倉合約的分別變化，其行使價在150.0美元至175.0美元之間。
過去 30 天的 AbbVie 期權交易量和未平倉合約
檢測到的重要期權交易：
符號 | 看跌/看漲 | 交易類型 | 情緒 | Exp。日期 | 問 | 出價 | 價格 | 行使價 | 總交易價格 | 未平倉合約 | 音量 |
|---|
ABBV | PUT | SWEEP | 看跌 | 11/15/24 | 7.7 美元 | 7.65 美元 | 7.7 美元 | 160.00 美元 | 90.8 萬美元 | 271 | 0 |
ABBV | CALL | SWEEP | 看跌 | 01/16/26 | 22.95 美元 | 22.2 美元 | 22.2 美元 | 155.00 美元 | 82.1 萬美元 | 137 | 37 |
ABBV | CALL | TRADE | 看漲 | 08/16/24 | 1.39 美元 | 1.25 美元 | 1.39 美元 | 175.00 美元 | 59.4 萬美元 | 4.1K | 438 |
ABBV | CALL | TRADE | 看漲 | 07/19/24 | 5.15 美元 | 4.95 美元 | 5.1 美元 | 160.00 美元 | 56.1 萬美元 | 285 | 135 |
ABBV | CALL | SWEEP | 看漲 | 06/21/24 | 0.63 美元 | 0.58 美元 | 0.63 美元 | 170.00 美元 | 47.2 萬美元 | 5.2K | 1.0K |
關於 AbbVie
艾伯維是一家制藥公司，在免疫學（與Humira、Skyrizi和Rinvoq合作）和腫瘤學（與Imbruvica和Venclexta合作）方面有着豐富的經驗。該公司於2013年初從雅培分拆出來。2020年對Allergan的收購增加了幾種美容領域的新產品和藥物（包括肉毒桿菌毒素）。
艾伯維現在站在哪裏？
分析師對艾伯維的看法
在過去的一個月中，3位行業分析師分享了他們對該股的見解，提出平均目標價爲189.0美元。
坎託·菲茨傑拉德的一位分析師將其評級下調至增持，新的目標股價爲200美元，這反映了人們的擔憂。
巴克萊銀行的一位分析師在評估中保持對AbbVie的增持評級，目標價爲187美元。
BMO Capital的一位分析師堅持對艾伯維的跑贏大盤評級，維持180美元的目標價。
交易期權涉及更大的風險，但也提供了更高利潤的潛力。精明的交易者通過持續的教育、戰略貿易調整、利用各種指標以及隨時關注市場動態來降低這些風險。使用Benzinga Pro獲取實時提醒，隨時了解AbbVie的最新期權交易。
